Feiba NF Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to presence of inhibitors in hemophilia patients, limited historical treatment alternatives, early plasma derived therapies, hospital centered bleeding management, surgical bleeding risks.

The growth in the forecast period can be attributed to rising hemophilia diagnosis rates, expansion of home infusion programs, improved inhibitor screening, growth in comprehensive hemophilia care centers, advancements in coagulation monitoring. Major trends in the forecast period include continued demand for bypassing agents, focus on bleeding control in inhibitor patients, growth in prophylactic hemophilia care, expansion of home based infusion therapy, improved safety monitoring in coagulation treatments.

The increasing prevalence of hemophilia is anticipated to drive the expansion of the FEIBA NF market in the coming years. Hemophilia is a rare inherited bleeding disorder in which the blood does not clot properly, leading to excessive bleeding after injuries or surgeries, as well as spontaneous internal bleeding. This rising prevalence is attributed to factors such as improved genetic testing, greater awareness and diagnosis, new mutations, and enhanced treatment options that contribute to longer life expectancy. FEIBA NF assists hemophilia patients by providing an effective treatment to manage bleeding episodes and support routine prophylaxis, thereby reducing the frequency of these episodes, improving long-term management, enhancing quality of life, and lowering the risks associated with hemophilia. For example, in June 2023, the National Library of Medicine, a US-based biomedical library, reported that hemophilia occurs in approximately 1 in 10,000 live births, affecting around 400,000 individuals worldwide. Hemophilia A is more prevalent, accounting for 80-85% of cases, occurring in 1 in 5,000 live male births, while Hemophilia B occurs in 1 in 30,000 live male births. Hemophilia C, caused by factor XI deficiency, is rarer, occurring in about 1 in 100,000 people, with a notable prevalence among Ashkenazi Jews (around 8%). Furthermore, in June 2023, The World Federation of Hemophilia (WFH), a Canada-based non-profit organization, reported that as of 2022, the estimated prevalence of hemophilia A was about 17.1 per 100,000 males for all cases, with 6 per 100,000 males for severe hemophilia A. For hemophilia B, prevalence rates were 3.8 per 100,000 males overall and 1.1 per 100,000 males for severe cases. Therefore, the growing prevalence of hemophilia is fueling the expansion of the FEIBA NF market.

The rising healthcare expenditure is expected to further support the growth of the FEIBA NF market. Healthcare expenditure refers to the total spending on health services and related activities over a specific period, typically measured annually. Factors contributing to increased healthcare spending include an aging population, chronic diseases, higher service costs, growing demand, technological progress, rising drug prices, the impact of COVID-19, medical inflation, and income disparities. This increased expenditure facilitates the development, approval, and availability of advanced treatments for hemophilia patients with inhibitors, ensuring access to life-saving therapies that control bleeding episodes and improve long-term management. For example, in May 2024, a report by the Office for National Statistics, a UK-based government department, noted that healthcare spending in the UK grew by 5.6% between 2022 and 2023, compared with 0.9% growth in 2022. Total UK healthcare expenditure reached approximately $317.63 billion (£292 billion) in 2023. Consequently, rising healthcare expenditure is driving the expansion of the FEIBA NF market.

A major trend in the FEIBA NF market is the focus on technological innovations, such as routine prophylaxis, to prevent frequent bleeding episodes in hemophilia patients with inhibitors. Routine prophylaxis involves preventive care aimed at lowering the risk of disease or complications through measures such as vaccinations, health screenings, or preemptive medications. For instance, in June 2023, Takeda Pharmaceuticals U.S.A. Inc., a US-based biopharmaceutical company, reported that FEIBA has been approved by the Food and Drug Administration (FDA). It is designed not only to manage bleeding episodes but also to provide routine prophylaxis to prevent or reduce the frequency of such episodes in hemophilia patients with inhibitors. This advancement strengthens its role in long-term hemophilia management, offering patients a proactive strategy for controlling their condition. Routine prophylaxis represents a significant improvement in treating hemophilia patients with inhibitors, helping to minimize bleeding episodes and enhance overall quality of life.

Major companies operating in the feiba nf market are Takeda Pharmaceuticals Inc.

North America was the largest region in the feiba NF market in 2025. The regions covered in the feiba nf market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the feiba nf market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the feiba nf market by increasing costs associated with plasma sourcing, fractionation processes, and cold chain distribution. These impacts are most evident in hospital and specialty pharmacy segments, especially in regions dependent on imported plasma derived products. Higher tariffs can strain healthcare budgets and affect treatment accessibility for rare bleeding disorders. However, tariffs are also supporting investments in regional plasma processing facilities, supply chain resilience, and long term self sufficiency in critical coagulation therapies.

The feiba nf market research report is one of a series of new reports that provides feiba nf market statistics, including feiba nf industry global market size, regional shares, competitors with a feiba nf market share, detailed feiba nf market segments, market trends and opportunities, and any further data you may need to thrive in the feiba nf industry. This feiba nf market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

FEIBA NF (Factor VIII Inhibitor Bypassing Activity) is a plasma-derived medication used to manage bleeding in hemophilia patients who have developed inhibitors against factors VIII or IX. It contains coagulation factors that bypass these inhibitors, promoting clot formation. It is indicated for controlling bleeding episodes and during surgical procedures, with careful monitoring for thromboembolic risks.

The main indications for the FEIBA NF market are hemophilia A and B with inhibitors, prophylactic treatment, and on-demand treatment. Hemophilia A and B are genetic disorders in which blood does not clot properly, leading to excessive bleeding. Patients with inhibitors have antibodies that neutralize the effectiveness of standard clotting factor therapies. The product is distributed through hospitals, specialty pharmacies, and direct-to-consumer channels, serving various end users, including both adult and pediatric patients.

The feiba NF market consists of sales of FEIBA NF 500 U, 1000 U, and 2500 U, and formulations offering 350-650 U and 700-1300 U per mL designed for managing bleeding in haemophilia patients with inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.